MaxCyte Stock Forward View - Simple Exponential Smoothing
| MXCT Stock | USD 0.81 -0.01 -1.22% |
Predicting MaxCyte's future price is a multi-variable problem that combines fundamental signals, technical structure, and market sentiment. This module focuses specifically on the hype and news dimension of that forecast.
At present, the short-cycle RSI for MaxCyte is 0, signaling extreme oversold conditions. Deeply oversold conditions like this sometimes attract bargain hunters, but can also persist during prolonged declines.Momentum
Sell Peaked
Oversold | Overbought |
EPS Estimate Next Quarter -0.09 | EPS Estimate Current Year -0.39 | EPS Estimate Next Year -0.30 | Wall Street Target Price 6.07 | EPS Estimate Current Quarter -0.10 |
The hype summary for MaxCyte aligns attention signals with price movement and peers. Options positioning and short interest provide sentiment context for MaxCyte in this view.
For additional insight, see Payables Turnover and Days Of Inventory On Hand.
MaxCyte Implied Volatility | 1.84 |
High implied volatility in MaxCyte's options signals that the market anticipates large price swings in MaxCyte stock. Conversely, low implied volatility indicates that investors expect relatively stable price action.
The Simple Exponential Smoothing forecasted value of MaxCyte on the next trading day is expected to be 0.81 with a mean absolute deviation of 0.03 and the sum of the absolute errors of 1.94.MaxCyte after-hype prediction price | $ 0.81 |
This sentiment summary adds context across forecasting, technical, analyst, and earnings perspectives for the stock.
Historical Fundamental Analysis of MaxCyte can be used to cross-verify projections for MaxCyte. The view supplies historical context for the projection discussion.Open Interest vs. 2026-04-17 MaxCyte Options
The open interest measure summarizes active contracts for MaxCyte and can be paired with trend context.
MaxCyte Additional Predictive Modules
Forecasting MaxCyte's price movement relies on structured analysis of indicator behavior, momentum signatures, and historical volatility patterns. Combining multiple forecasting approaches can reduce model-specific bias and improve reliability.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Simple Exponential Smoothing Price Forecast For the 18th of March 2026
Given 90 days horizon, the Simple Exponential Smoothing forecasted value of MaxCyte on the next trading day is expected to be 0.81 with a mean absolute deviation of 0.03 , mean absolute percentage error of 0.0016 , and the sum of the absolute errors of 1.94 .Please note that although there have been many attempts to predict MaxCyte Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that MaxCyte's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest MaxCyte | MaxCyte Price Prediction | Research Analysis |
Forecasted Value
The next-day forecast for MaxCyte focuses on identifying predictive downside and upside bands that can frame a realistic trading range. At the moment, the model places downside around 0.01 and upside around 4.54 for the forecasting period.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of MaxCyte stock data series using in forecasting. Note that when a statistical model is used to represent MaxCyte stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 111.697 |
| Bias | Arithmetic mean of the errors | 0.0108 |
| MAD | Mean absolute deviation | 0.0318 |
| MAPE | Mean absolute percentage error | 0.0308 |
| SAE | Sum of the absolute errors | 1.94 |
The concept of mean reversion suggests that MaxCyte's price will eventually return toward its long-run average. High prices may deter value investors, while unusually low prices often attract buyers who anticipate a recovery.
After-Hype Price Density Analysis
The price distribution graph for MaxCyte visualizes the statistical uncertainty around our prediction model's output. Investors should interpret the full distribution of MaxCyte's outcomes, not just the central tendency, when making decisions.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
The downside and upside margins for MaxCyte after major news events are estimated from historical precedent. MaxCyte's after-hype downside and upside margins for the prediction period are 0.04 and 4.53, respectively. This approach captures the empirical distribution of MaxCyte's short-term price reactions without assuming any particular model of future behavior.
Current Value
This after-hype projection for MaxCyte uses a 3 months horizon to examine how price may behave after short-term sentiment effects dissipate. The objective is to separate event-driven enthusiasm from a more stable price path once the market absorbs the catalyst.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as MaxCyte is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MaxCyte backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with MaxCyte, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.94 | 3.73 | 0.06 | 0.06 | 8 Events | 8 Events | In 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.81 | 0.81 | 0.00 |
|
Hype Timeline
MaxCyte is now traded for 0.81. The company has historical hype elasticity of -0.06, and average elasticity to hype of competition of -0.06. MaxCyte is forecasted not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is forecasted to be very small, whereas the daily expected return is now at -0.94%. %. The volatility of related hype on MaxCyte is about 6016.13%, with the expected price after the next announcement by competition of 0.75. About 76.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.49. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MaxCyte recorded a loss per share of 0.43. The company had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in 8 days. Historical Fundamental Analysis of MaxCyte can be used to cross-verify projections for MaxCyte. The view supplies historical context for the projection discussion.Related Hype Analysis
The relationship between MaxCyte and its sector peers means that news affecting one company often reverberates across MaxCyte's competitive landscape. Tracking peer hype helps investors anticipate MaxCyte's likely short-term price behavior.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| PROF | Profound Medical Corp | 0.19 | 7 per month | 0.00 | -0.04 | 5.94 | -7.33 | 38.55 | |
| TLSI | TriSalus Life Sciences | -0.48 | 10 per month | 0.00 | -0.15 | 5.49 | -7.79 | 26.66 | |
| AVR | Anteris Technologies Global | -0.13 | 6 per month | 3.47 | 0.11 | 9.42 | -5.99 | 25.09 | |
| LNSR | LENSAR Inc | -0.59 | 13 per month | 0.00 | -0.04 | 2.72 | -3.27 | 20.36 | |
| OWLT | Owlet Inc | 0.21 | 9 per month | 0.00 | -0.21 | 6.04 | -11.88 | 44.66 | |
| CATX | Perspective Therapeutics | 0.14 | 11 per month | 4.96 | 0.15 | 11.81 | -8.83 | 77.44 | |
| PRE | Prenetics Global | 0.93 | 8 per month | 4.20 | 0.15 | 13.33 | -7.28 | 27.11 | |
| ARMP | Armata Pharmaceuticals | -0.64 | 4 per month | 4.90 | 0.14 | 14.07 | -8.06 | 34.69 | |
| NNOX | Nano X Imaging | -0.19 | 6 per month | 0.00 | -0.14 | 6.31 | -6.23 | 15.50 | |
| SGMO | Sangamo Therapeutics | -0.06 | 9 per month | 0.00 | -0.02 | 7.89 | -7.50 | 73.25 |
Other Forecasting Options for MaxCyte
Whether a novice or experienced investor, anyone considering MaxCyte needs to understand the dynamics of MaxCyte's price movement. Price charts for MaxCyte Stock contain a significant amount of noise that can distort investment decisions.MaxCyte Related Equities
The following equities are related to MaxCyte within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing MaxCyte against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
MaxCyte Market Strength Events
Analyzing market strength indicators for MaxCyte enables investors to understand how the stock performs relative to overall market momentum. These indicators are valuable tools for identifying when to enter or exit positions in MaxCyte.
| Accumulation Distribution | 42233.14 | |||
| Daily Balance Of Power | -0.17 | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 0.81 | |||
| Day Typical Price | 0.81 | |||
| Price Action Indicator | -0.01 | |||
| Period Momentum Indicator | -0.01 |
MaxCyte Risk Indicators
Identifying and analyzing MaxCyte's key risk indicators is a foundational step in projecting how its price may evolve. This process helps investors quantify the risk associated with MaxCyte's and decide how to manage it.
| Mean Deviation | 2.87 | |||
| Standard Deviation | 3.66 | |||
| Variance | 13.39 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for MaxCyte
The amount of media and story coverage tied to MaxCyte can signal where market attention is concentrating at the moment. Used properly, this context can help investors judge whether visibility is reinforcing the thesis or attracting more speculative pressure.
Contributor Headline
Latest Perspective From Macroaxis
MaxCyte Short Properties
Short sentiment tied to MaxCyte matters because heavier bearish pressure can change how quickly future price expectations become unstable. This is most valuable when investors want to know whether bearish pressure is starting to shape the market's reaction function.
| Common Stock Shares Outstanding | 104.8 M | |
| Cash And Short Term Investments | 154.5 M |
Additional Tools for MaxCyte Stock Analysis
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Stocks Directory Find actively traded stocks across global markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |